loading
Kymera Therapeutics Inc stock is traded at $25.97, with a volume of 468.79K. It is up +3.80% in the last 24 hours and down -24.70% over the past month. Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
See More
Previous Close:
$25.02
Open:
$25
24h Volume:
468.79K
Relative Volume:
0.71
Market Cap:
$1.65B
Revenue:
$87.56M
Net Income/Loss:
$-167.47M
P/E Ratio:
-11.10
EPS:
-2.34
Net Cash Flow:
$-148.20M
1W Performance:
+15.94%
1M Performance:
-24.70%
6M Performance:
-43.85%
1Y Performance:
-23.07%
1-Day Range:
Value
$24.72
$26.03
1-Week Range:
Value
$22.05
$26.05
52-Week Range:
Value
$19.45
$53.27

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Name
Name
Kymera Therapeutics Inc
Name
Phone
857-285-5314
Name
Address
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Name
Employee
188
Name
Twitter
Name
Next Earnings Date
2025-02-21
Name
Latest SEC Filings
Name
KYMR's Discussions on Twitter

Compare KYMR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
KYMR
Kymera Therapeutics Inc
25.97 1.65B 87.56M -167.47M -148.20M -2.34
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
489.10 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.16 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
596.20 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
234.56 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
230.98 26.16B 3.81B -644.79M -669.77M -6.24

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-13-25 Initiated Citigroup Buy
Dec-10-24 Initiated BTIG Research Buy
Dec-06-24 Initiated BMO Capital Markets Market Perform
Dec-02-24 Upgrade Wells Fargo Equal Weight → Overweight
Nov-18-24 Initiated Stephens Overweight
Sep-09-24 Resumed Leerink Partners Outperform
Aug-26-24 Upgrade Wolfe Research Peer Perform → Outperform
Apr-22-24 Initiated Oppenheimer Outperform
Feb-15-24 Initiated Wolfe Research Peer Perform
Jan-04-24 Upgrade JP Morgan Neutral → Overweight
Jan-03-24 Downgrade BofA Securities Buy → Neutral
Dec-19-23 Downgrade Wells Fargo Overweight → Equal Weight
Jun-30-23 Initiated Truist Buy
May-05-23 Upgrade Raymond James Mkt Perform → Outperform
Dec-06-22 Downgrade Credit Suisse Outperform → Neutral
Nov-08-22 Initiated Raymond James Mkt Perform
Aug-15-22 Initiated Jefferies Buy
Aug-03-22 Initiated Goldman Buy
Jul-20-22 Initiated SVB Leerink Mkt Perform
Apr-28-22 Initiated Credit Suisse Outperform
Mar-10-22 Initiated JP Morgan Neutral
Feb-10-22 Initiated Wells Fargo Overweight
Sep-30-21 Initiated B. Riley Securities Neutral
Sep-30-21 Initiated Stifel Buy
Sep-10-21 Downgrade BofA Securities Buy → Neutral
May-21-21 Initiated UBS Buy
Apr-14-21 Initiated Berenberg Buy
Dec-04-20 Initiated H.C. Wainwright Buy
Sep-15-20 Initiated BofA Securities Neutral
Sep-15-20 Initiated Cowen Outperform
Sep-15-20 Initiated Guggenheim Buy
Sep-15-20 Initiated Morgan Stanley Equal-Weight
View All

Kymera Therapeutics Inc Stock (KYMR) Latest News

pulisher
Apr 17, 2025

Learn to Evaluate (KYMR) using the Charts - news.stocktradersdaily.com

Apr 17, 2025
pulisher
Apr 11, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $56.36 Consensus Target Price from Analysts - Defense World

Apr 11, 2025
pulisher
Apr 10, 2025

Kymera Therapeutics (KYMR) Moves 13.8% Higher: Will This Strength Last? - MSN

Apr 10, 2025
pulisher
Apr 10, 2025

Kymera Therapeutics Appoints Noah Goodman as Chief Business Offi - GuruFocus

Apr 10, 2025
pulisher
Apr 10, 2025

Kymera Therapeutics appoints new Chief Business Officer - Investing.com Australia

Apr 10, 2025
pulisher
Apr 09, 2025

Kymera Therapeutics appoints new Chief Business Officer By Investing.com - Investing.com South Africa

Apr 09, 2025
pulisher
Apr 09, 2025

Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer - citybiz

Apr 09, 2025
pulisher
Apr 09, 2025

Strategic Power Move: Kymera Lands M&A Expert to Accelerate Drug Development Deals - Stock Titan

Apr 09, 2025
pulisher
Apr 07, 2025

Kymera stock touches 52-week low at $20.77 amid market challenges - Investing.com Australia

Apr 07, 2025
pulisher
Apr 07, 2025

Kymera stock touches 52-week low at $20.77 amid market challenges By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 07, 2025

Vanguard Group Inc. Raises Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Apr 07, 2025
pulisher
Apr 06, 2025

KLP Kapitalforvaltning AS Makes New Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Apr 06, 2025
pulisher
Apr 01, 2025

(KYMR) Trading Report - news.stocktradersdaily.com

Apr 01, 2025
pulisher
Apr 01, 2025

Teacher Retirement System of Texas Increases Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

Kymera stock touches 52-week low at $28.75 amid market challenges - Investing.com Australia

Mar 31, 2025
pulisher
Mar 27, 2025

Swiss National Bank Buys 10,300 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Mar 27, 2025
pulisher
Mar 27, 2025

Kymera at H.C. Wainwright Conference: Strategic Moves in Immunology By Investing.com - Investing.com Canada

Mar 27, 2025
pulisher
Mar 21, 2025

Victory Capital Management Inc. Raises Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Mar 21, 2025
pulisher
Mar 21, 2025

Charles Schwab Investment Management Inc. Increases Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Mar 21, 2025
pulisher
Mar 21, 2025

Analyzing Big Cypress Acquisition (OTCMKTS:BCYP) and Kymera Therapeutics (NASDAQ:KYMR) - Defense World

Mar 21, 2025
pulisher
Mar 18, 2025

Bank of New York Mellon Corp Has $5.11 Million Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Mar 18, 2025
pulisher
Mar 15, 2025

Citigroup Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR) - Defense World

Mar 15, 2025
pulisher
Mar 14, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Citigroup Initiates Coverage of Kymera Therapeutics (KYMR) with Buy Recommendation - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Citigroup starts coverage of Kymera with $52 PT - TradingView

Mar 13, 2025
pulisher
Mar 11, 2025

(KYMR) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Mar 11, 2025
pulisher
Mar 07, 2025

Why Kymera Therapeutics’ Stock is Making Waves - TipRanks

Mar 07, 2025
pulisher
Mar 06, 2025

Kymera at TD Cowen Conference: Focus on Clinical Advancements By Investing.com - Investing.com UK

Mar 06, 2025
pulisher
Mar 06, 2025

Don't Ignore The Insider Selling In Kymera Therapeutics - Simply Wall St

Mar 06, 2025
pulisher
Mar 06, 2025

Time To Worry? Analysts Just Downgraded Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Outlook - Yahoo Finance

Mar 06, 2025
pulisher
Mar 06, 2025

What is B. Riley’s Forecast for KYMR FY2025 Earnings? - Defense World

Mar 06, 2025
pulisher
Mar 05, 2025

A Guide To The Risks Of Investing In Kymera Therapeutics Inc (KYMR) - Knox Daily

Mar 05, 2025
pulisher
Mar 05, 2025

New York State Common Retirement Fund Reduces Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Mar 05, 2025
pulisher
Mar 05, 2025

Financial Review: Kymera Therapeutics (NASDAQ:KYMR) vs. Cardiff Oncology (NASDAQ:CRDF) - Defense World

Mar 05, 2025
pulisher
Mar 05, 2025

Equities Analysts Offer Predictions for KYMR Q1 Earnings - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Kymera Therapeutics announces new performance-based stock plan By Investing.com - Investing.com Australia

Mar 04, 2025
pulisher
Mar 03, 2025

Kymera Therapeutics COO sells $42,113 in stock By Investing.com - Investing.com South Africa

Mar 03, 2025
pulisher
Mar 03, 2025

Kymera Therapeutics’ chief legal officer sells $68,239 in stock By Investing.com - Investing.com South Africa

Mar 03, 2025
pulisher
Mar 03, 2025

Kymera Therapeutics CFO sells shares worth $214,219 By Investing.com - Investing.com South Africa

Mar 03, 2025
pulisher
Mar 03, 2025

Kymera Therapeutics’ chief medical officer sells shares worth $174,785 By Investing.com - Investing.com Canada

Mar 03, 2025
pulisher
Mar 03, 2025

Kymera Therapeutics CFO sells shares worth $214,219 - Investing.com India

Mar 03, 2025
pulisher
Mar 03, 2025

Kymera Therapeutics’ chief medical officer sells shares worth $174,785 - Investing.com

Mar 03, 2025
pulisher
Mar 03, 2025

Kymera Therapeutics COO sells $42,113 in stock - Investing.com

Mar 03, 2025
pulisher
Mar 03, 2025

Kymera Therapeutics announces new performance-based stock plan - Investing.com India

Mar 03, 2025
pulisher
Mar 03, 2025

Kymera Therapeutics Grants Performance Stock Units to Executives - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Rhumbline Advisers Acquires 1,861 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Mar 03, 2025

Kymera Therapeutics Inc Stock (KYMR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.04
price up icon 2.51%
$72.65
price up icon 3.49%
$32.60
price up icon 1.27%
$24.61
price up icon 6.77%
$98.76
price up icon 0.52%
biotechnology ONC
$230.98
price up icon 1.24%
Cap:     |  Volume (24h):